Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In VivoGangyang Wang(Shanghai Jiao Tong University), Chenhao Zhou(Shanghai Jiao Tong University)Frontiers in PharmacologyJanuary 17, 202210.3389/fphar.2021.798837Cited by 23SaveCiteExport RISWatch citationsRelated PapersDisruption of SLFN11 Deficiency–Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti–PD-1 Therapy Efficacy in Hepatocellular Carcinoma|Gastroenterology|2023|109